A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.

Raphael Pharma

Status: Active, not recruiting

Conditions: Inflammatory Disease; Rheumatoid Arthritis

Treatments: Dietary Supplement: Cannabigerol (CBG)

Study type: Interventional

Funder types: Industry

Identifiers

NCT06513507

20441

Details and patient eligibility

About

This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis using laboratory and self-reported outcome measures.

Enrollment: 12 patients

Sex: All

Ages: 25+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, over 25 years of age
• Positive anti-CCP blood test
• Active RA-related inflammation with at least 2 swollen joints
• University graduate
• Generally healthy with no uncontrolled chronic disease
• Able to read, understand, and sign informed consent
• Resides in the USA
• Willing to comply with study requirements and avoid other cannabis products during the study period

Exclusion criteria

• Pre-existing chronic conditions preventing adherence
• Severe allergic reactions requiring an Epi-pen
• Use of opiates in the last 4 weeks or cannabis in the last 8 weeks
• Pregnant or breastfeeding women
• Recent invasive medical procedure or surgery
• Active malignancy or ongoing oncology treatment
• Use of cytochrome P450 or 3A4 inhibitors
• History of substance abuse

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

12 participants in 1 patient group

CBG Treatment

Experimental group

Description:

Participants will receive 0.5 milliliters of purified cannabigerol (CBG) in sesame oil once daily in the evening for a duration of eight weeks.

Treatment:

Dietary Supplement: Cannabigerol (CBG)